ZFGN Zafgen

Zafgen Reports Third Quarter 2019 Financial Results

Zafgen Reports Third Quarter 2019 Financial Results

Evaluation of strategic alternatives ongoing

BOSTON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) today reported its third quarter 2019 financial results.

In September 2019, Zafgen announced plans to explore strategic options to maximize shareholder value and these efforts are ongoing. The potential strategic alternatives that may be evaluated include, but are not limited to, an acquisition, merger, business combination, in-licensing, or other strategic transaction involving the Company or its assets.

Third Quarter 2019 Financial Results

Cash, Cash Equivalents and Marketable Securities

As of September 30, 2019, the Company had cash, cash equivalents, and marketable securities totaling $82.0 million. Based on previously announced and recently implemented plans to reduce operating expenses and prioritize key resources announced previously, Zafgen expects significantly reduced cash burn in its future quarters compared to the third quarter of 2019.

Net Loss

The Company reported a net loss for the third quarter of 2019 of $12.9 million, or $0.35 per share, compared to a net loss of $15.1 million, or $0.41 per share, for the third quarter of 2018. The net loss for the third quarter of 2019 includes $4.0 million of restructuring charges.

The weighted average common shares (basic and diluted) outstanding used to compute net loss per share were 37.4 million for the third quarter of 2019 compared to 36.6 million for the same quarter of 2018.

Research and Development Expenses

Research and development expenses for the third quarter of 2019 were $5.3 million compared to $11.8 million for the third quarter of 2018. The decrease in research and development expenses compared to the prior year period was primarily due to lower spend to resolve the FDA clinical hold and decreased personnel related costs.

Restructuring Charges

Restructuring charges for the third quarter of 2019 were $4.0 million and include personnel related costs primarily related to severance expenses as a result of the multiple reductions in workforce and contract termination costs implemented in the third quarter of 2019.

General and Administrative Expenses

General and administrative expenses for the third quarter of 2019 were $3.6 million, compared to $3.3 million for the third quarter of 2018. The increase in general and administrative expenses as compared to the prior year period was primarily due to an increase in professional fees related to strategic alternatives activities and legal fees, which were partially offset by a decrease in non-cash stock-based compensation.

About Zafgen

Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company that has leveraged its proprietary MetAP2 biology platform to pioneer the study of MetAP2 inhibitors in both common and rare metabolic disorders. Learn more at .

As previously announced, the Company has retained MTS Health Partners L.P. as its exclusive advisor to assist the Company in exploring alternatives. There can be no assurance that the exploration of strategic alternatives will result in any transaction being entered into or consummated. The Company has not set a timetable for completion of this review process and the Company does not intend to comment further unless or until the Board of Directors has approved a definitive course of action, the review process is concluded, or it is determined that other disclosure is appropriate.

Safe Harbor Statement 

Various statements in this release concerning Zafgen's future expectations, plans and prospects, including without limitation,  Zafgen’s plans to explore strategic alternatives, Zafgen’s expected cash, cash equivalents and marketable securities balance as of September 30, 2019, and Zafgen’s expectations regarding the length of its cash runway, may constitute forward-looking statements for the purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation,  Zafgen’s ability to explore strategic alternatives and enter into and consummate a transaction as a result of such process, Zafgen’s ability to retain personnel, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in Zafgen's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in Zafgen's subsequent filings with the Securities and Exchange Commission, including without limitation Zafgen’s Quarterly Reports on Form 10-Q. In addition, any forward-looking statements represent Zafgen's views only as of today and should not be relied upon as representing its views as of any subsequent date. Zafgen explicitly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Media/Investor Relations Contacts:

Zafgen, Inc.

Patricia Allen

Chief Financial Officer

617-648-9792

Media

Krystle Gibbs

Ten Bridge Communications 



508-479-6358

Investors

John Woolford

Westwicke



443-213-0506



ZAFGEN, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share data)
(Unaudited)
         
  Three Months Ended September 30, Nine Months Ended September 30,
   2019   2018   2019   2018 
Revenue $-  $-  $-  $- 
Operating expenses:        
Research and development  5,260   11,830   23,463   36,472 
General and administrative  3,627   3,339   10,891   9,959 
Restructuring charges  4,019   -   4,019   - 
Total operating expenses  12,906   15,169   38,373   46,431 
Loss from operations  (12,906)  (15,169)  (38,373)  (46,431)
Other income (expense):        
Interest income  451   623   1,654   1,214 
Interest expense  (426)  (475)  (1,404)  (1,399)
Foreign currency transaction losses, net  (33)  (46)  (32)  (182)
Total other income (expense), net  (8)  102   218   (367)
Net loss  (12,914) $(15,067)  (38,155) $(46,798)
Net loss per share, basic and diluted  (0.35) $(0.41)  (1.02) $(1.53)
Weighted average common shares outstanding, basic and diluted  37,369,829   36,619,575   37,337,081   30,608,664 
         





ZAFGEN, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
(Unaudited)
     
  September 30,December 31,
   2019   2018 
     
Assets    
Current assets:    
Cash and cash equivalents $43,337  $49,331 
Marketable securities  38,669   68,735 
Tax incentive receivable  235   1,536 
Prepaid expenses and other current assets  1,202   1,728 
Total current assets  83,443   121,330 
Property and equipment, net  913   375 
Operating lease right-of-use assets  7,172   - 
Restricted cash  1,339   - 
Other assets  20   57 
Total assets $92,887  $121,762 
Liabilities and Stockholders' Equity    
Current liabilities:    
Accounts payable $3,319  $3,590 
Accrued expenses  1,719   4,261 
Accrued restructuring costs  3,619   - 
Operating lease liabilities, current  409   - 
Notes payable, current  7,273   5,455 
Total current liabilities  16,339   13,306 
Notes payable, long-term  10,166   15,185 
Operating lease liabilities  6,502   - 
Total liabilities  33,007   28,491 
Stockholders' equity:    
Preferred stock; $0.001 par value per share; 5,000,000 shares authorized as of September 30, 2019 and December 31, 2018; no shares issued and outstanding as of September 30, 2019 and December 31, 2018  -   - 
Common stock, $0.001 par value per share; 115,000,000 shares authorized as of September 30, 2019 and December 31, 2018; 37,370,301 and 37,287,221 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively  37   37 
Additional paid-in capital  448,902   444,212 
Accumulated deficit  (389,100)  (350,945)
Accumulated other comprehensive income (loss)  41   (33)
Total stockholders' equity  59,880   93,271 
Total liabilities and stockholders' equity $92,887  $121,762 
     

EN
06/11/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zafgen

Ashiq Mubarack ... (+9)
  • Ashiq Mubarack
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe
ZFGN ZAFGEN
BLUE BLUEBIRD BIO INC.
XOMA XOMA
XNCR XENCOR INC.
VYGR VOYAGER THERAPEUTICS INC.
STML STEMLINE THERAPEUTICS INC
SGMO SANGAMO THERAPEUTICS INC.
SAGE SAGE THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PRTK PARATEK PHARMACEUTICALS INC
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
MYOK MYOKARDIA INC.
MGNX MACROGENICS INC.
LXRX LEXICON PHARMACEUTICALS INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
ICPT INTERCEPT PHARMACEUTICALS INC.
GBT GLOBAL BLOOD THERAPEUTICS INC
FPRX FIVE PRIME THERAPEUTICS INC.
FATE FATE THERAPEUTICS INC
EPZM EPIZYME INC.
EIGR EIGER BIOPHARMACEUTICALS
CTMX CYTOMX THERAPEUTICS INC.
CDTX CIDARA THERAPEUTICS
CATB CATABASIS PHARMACEUTICALS
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ALXN ALEXION PHARMACEUTICALS INC.
AIMT AIMMUNE THERAPEUTICS INC
AGTC APPLIED GENETIC TECHNOLOGIES
ACOR ACORDA THERAPEUTICS INC.
ABUS ARBUTUS BIOPHARMA CORP.
ALPN ALPINE SELECT AG
SYRS SYROS PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
NTLA INTELLIA THERAPEUTICS INC.
MRUS MERUS B V
ALBO ALBIREO PHARMA
MGEN MIRAGEN THERAPEUTICS
ANAB ANAPTYSBIO INC.
OBSN OBSEVA
KALA KALA PHARMACEUTICALS INC.
NBRV NABRIVA THERAPEUTICS PLC
MRSN MERSANA THERAPEUTICS
SYBX SYNLOGIC
GTHX G1 THERAPEUTICS
BHVN BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
VRNA VERONA PHARMA ADS
ALNA ALLENA PHARMACEUTICALS
ARGX ARGEN-X SE
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
TORC RESTORBIO INC
UMRX UNUM THERAPEUTICS
IDRA IDERA PHARMACEUTICALS
AVRO AVROBIO
SRRK SCHOLAR ROCK HOLDING CORPORATION
APTX APTINYX
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
MGTA MAGENTA THERAPEUTICS
ETTX ENTASIS THERAPEUTICS HOLDINGS
ARAV ARAVIVE
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
AQST AQUESTIVE THERAPEUTICS
RGLS INC.
ORTX REGULUS THERAPEUTICS
HARP ORCHARD THERAPEUTICS
TCRR HARPOON THERAPEUTICS
FENC TCR2 THERAPEUTICS
TPTX FENNEC PHARMA
ISEE TURNING POINT THERAPEUTICS
PRVL IVERIC BIO
MLND PREVAIL THERAPEUTICS
KRTX MILLENDO THERAPEUTICS
STOK KARUNA THERAPEUTICS INC.
SWTX STOKE THERAPEUTICS
SPRINGWORKS THERAPEUTICS
Ashiq Mubarack ... (+9)
  • Ashiq Mubarack
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe
ZFGN ZAFGEN
BLUE BLUEBIRD BIO INC.
XOMA XOMA
XNCR XENCOR INC.
VYGR VOYAGER THERAPEUTICS INC.
STML STEMLINE THERAPEUTICS INC
SGMO SANGAMO THERAPEUTICS INC.
SAGE SAGE THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PRTK PARATEK PHARMACEUTICALS INC
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
MYOK MYOKARDIA INC.
MGNX MACROGENICS INC.
LXRX LEXICON PHARMACEUTICALS INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
ICPT INTERCEPT PHARMACEUTICALS INC.
GBT GLOBAL BLOOD THERAPEUTICS INC
FPRX FIVE PRIME THERAPEUTICS INC.
FATE FATE THERAPEUTICS INC
EPZM EPIZYME INC.
EIGR EIGER BIOPHARMACEUTICALS
CTMX CYTOMX THERAPEUTICS INC.
CDTX CIDARA THERAPEUTICS
CATB CATABASIS PHARMACEUTICALS
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ALXN ALEXION PHARMACEUTICALS INC.
AIMT AIMMUNE THERAPEUTICS INC
AGTC APPLIED GENETIC TECHNOLOGIES
ACOR ACORDA THERAPEUTICS INC.
ABUS ARBUTUS BIOPHARMA CORP.
ALPN ALPINE SELECT AG
SYRS SYROS PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
NTLA INTELLIA THERAPEUTICS INC.
MRUS MERUS B V
ALBO ALBIREO PHARMA
MGEN MIRAGEN THERAPEUTICS
ANAB ANAPTYSBIO INC.
OBSN OBSEVA
KALA KALA PHARMACEUTICALS INC.
NBRV NABRIVA THERAPEUTICS PLC
MRSN MERSANA THERAPEUTICS
SYBX SYNLOGIC
GTHX G1 THERAPEUTICS
BHVN BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
VRNA VERONA PHARMA ADS
ALNA ALLENA PHARMACEUTICALS
ARGX ARGEN-X SE
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
TORC RESTORBIO INC
UMRX UNUM THERAPEUTICS
IDRA IDERA PHARMACEUTICALS
AVRO AVROBIO
SRRK SCHOLAR ROCK HOLDING CORPORATION
APTX APTINYX
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
MGTA MAGENTA THERAPEUTICS
ETTX ENTASIS THERAPEUTICS HOLDINGS
ARAV ARAVIVE
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
AQST AQUESTIVE THERAPEUTICS
RGLS INC.
ORTX REGULUS THERAPEUTICS
HARP ORCHARD THERAPEUTICS
TCRR HARPOON THERAPEUTICS
FENC TCR2 THERAPEUTICS
TPTX FENNEC PHARMA
ISEE TURNING POINT THERAPEUTICS
PRVL IVERIC BIO
MLND PREVAIL THERAPEUTICS
KRTX MILLENDO THERAPEUTICS
STOK KARUNA THERAPEUTICS INC.
SWTX STOKE THERAPEUTICS
SPRINGWORKS THERAPEUTICS
Kambiz Yazdi ... (+3)
  • Kambiz Yazdi
  • Liana Moussatos
  • Shveta Dighe
 PRESS RELEASE

Zafgen Reports Fourth Quarter and Full Year 2019 Financial Results

Zafgen Reports Fourth Quarter and Full Year 2019 Financial Results Zafgen and Chondrial Therapeutics previously announced a definitive merger agreement Merger creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases Transaction expected to close in the second quarter of 2020 BOSTON, March 05, 2020 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) today reported its fourth quarter and full year 2019 financial results. In December 2019, Zafgen and Chondrial Therapeutics, Inc., announced that the two companies...

Ashiq Mubarack ... (+9)
  • Ashiq Mubarack
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe
ZFGN ZAFGEN
BLUE BLUEBIRD BIO INC.
XOMA XOMA
XNCR XENCOR INC.
VYGR VOYAGER THERAPEUTICS INC.
STML STEMLINE THERAPEUTICS INC
SGMO SANGAMO THERAPEUTICS INC.
SAGE SAGE THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PRTK PARATEK PHARMACEUTICALS INC
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
MYOK MYOKARDIA INC.
MGNX MACROGENICS INC.
LXRX LEXICON PHARMACEUTICALS INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
ICPT INTERCEPT PHARMACEUTICALS INC.
GBT GLOBAL BLOOD THERAPEUTICS INC
FPRX FIVE PRIME THERAPEUTICS INC.
FATE FATE THERAPEUTICS INC
EPZM EPIZYME INC.
EIGR EIGER BIOPHARMACEUTICALS
CTMX CYTOMX THERAPEUTICS INC.
CDTX CIDARA THERAPEUTICS
CATB CATABASIS PHARMACEUTICALS
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ALXN ALEXION PHARMACEUTICALS INC.
AIMT AIMMUNE THERAPEUTICS INC
AGTC APPLIED GENETIC TECHNOLOGIES
ACOR ACORDA THERAPEUTICS INC.
ABUS ARBUTUS BIOPHARMA CORP.
ALPN ALPINE SELECT AG
SYRS SYROS PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
NTLA INTELLIA THERAPEUTICS INC.
MRUS MERUS B V
ALBO ALBIREO PHARMA
MGEN MIRAGEN THERAPEUTICS
ANAB ANAPTYSBIO INC.
OBSN OBSEVA
KALA KALA PHARMACEUTICALS INC.
NBRV NABRIVA THERAPEUTICS PLC
MRSN MERSANA THERAPEUTICS
SYBX SYNLOGIC
GTHX G1 THERAPEUTICS
BHVN BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
VRNA VERONA PHARMA ADS
ALNA ALLENA PHARMACEUTICALS
ARGX ARGEN-X SE
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
TORC RESTORBIO INC
UMRX UNUM THERAPEUTICS
IDRA IDERA PHARMACEUTICALS
AVRO AVROBIO
SRRK SCHOLAR ROCK HOLDING CORPORATION
APTX APTINYX
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
MGTA MAGENTA THERAPEUTICS
ETTX ENTASIS THERAPEUTICS HOLDINGS
ARAV ARAVIVE
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
AQST AQUESTIVE THERAPEUTICS
RGLS INC.
ORTX REGULUS THERAPEUTICS
HARP ORCHARD THERAPEUTICS
TCRR HARPOON THERAPEUTICS
FENC TCR2 THERAPEUTICS
TPTX FENNEC PHARMA
ISEE TURNING POINT THERAPEUTICS
PRVL IVERIC BIO
MLND PREVAIL THERAPEUTICS
KRTX MILLENDO THERAPEUTICS
STOK KARUNA THERAPEUTICS INC.
SWTX STOKE THERAPEUTICS
SPRINGWORKS THERAPEUTICS

ResearchPool Subscriptions

Get the most out of your insights

Get in touch